BERWYN, Pa.–(BUSINESS WIRE)–The AscellaHealth Family of Companies, including AscellaHealth, a global healthcare solutions and specialty pharmacy company, and subsidiaries Optime Care and Terebellum, announces its founding sponsorship of the inaugural Gene Therapy and Specialty Pharmacy Awareness Month, September 2022, which was accepted for inclusion in the Annual Calendar of Health Observations and Recognition Days, published by The Society for Health Care Strategy & Market Development (SHSMD) of the American Hospital Association. This annual compliance creates an important platform for patients, payers, life science manufacturers and suppliers – all stakeholders in the Specialty Pharmacy (SP) continuum of care – to raise awareness in their communities about new and emerging new therapies, report on trends in the sector and exchange information on innovative financial solutions to offset the high costs of these treatments.
Dea Belazi, President and CEO of AscellaHealth Family of Companies, said: “These industry spotlight raises the profile of more than 900 new drug discovery applications for ongoing clinical trials of ongoing gene therapy products, expected FDA approvals of 10 to 20 gene therapies in in the coming year and the availability of more than 500 specialty drugs that currently account for up to 52% of an employer’s total pharmacy expenditures.AscellaHealth appreciates its position at the center of these discussions and is pleased to become a steward of information and awareness related to specialty and rare disease drugs that are dramatically changing the treatment landscape for millions of people.”
Multi-million dollar drugs have arrived with a new record set last month when the U.S. Food and Drug Administration approved Zynteglo, a gene therapy for patients’ beta thalassemia, a rare condition that requires regular blood transfusions and carries a record price tag of $2. 8 million hanging. making it the most expensive single-use drug in the US and one of the highest worldwide. Others, such as Zolgensma, which treats spinal muscular atrophy (SMA), costs $2.1 million for a single-dose treatment and Luxturna for genetic blindness costs $850,000.
“In time, the gene and cell therapy market is expected to go beyond rare diseases,” says Belazi. “At AscellaHealth, we have introduced unique financial solutions that address accessibility and affordability issues.”
About the AscellaHealth family of companies
The AscellaHealth Family of Companies, comprised of AscellaHealth and its subsidiaries Optime Care and Terebellum, is a global healthcare and specialty pharmaceuticals solutions organization serving specialty and rare diseases, patients, payers, life science manufacturers and suppliers with solutions to the unmet needs in this dynamic environment. market. A unique patient-centric mission and commitment to improved drug access and outcomes are intertwined with integrated end-to-end solutions spanning the entire pharmaceutical lifecycle and beyond. Visit www.AscellaHealth.com.